GlassScriptPhysician profile
Gunjan M Modi
NPI 1356589204
$1,905.68
in general payments reported to CMS, 2019-2025
15 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.26 · 2020: $390 · 2021: $414 · 2022: $202 · 2023: $142 · 2024: $531 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $747.16 | 2020-2021 | |
| Kerecis Limited | $444.54 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Regeneron Healthcare Solutions, INC. | $238.40 | 2021-2025 | Dupixent, Libtayo |
| Bioventus LLC | $195.36 | 2022-2023 | |
| Incyte Corporation | $60.79 | 2024-2025 | Opzelura |
| Lilly USA, LLC | $43.22 | 2022-2025 | Taltz, Ebglyss |
| Mimedx Group, INC. | $37.40 | 2024 | |
| Ucb, INC. | $25.92 | 2019 | |
| Genentech USA, INC. | $20.75 | 2022 | |
| Organogenesis INC. | $19.84 | 2023 | Puraply |
| Almirall LLC | $16.51 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.13 | 2022 | |
| Merck Sharp & Dohme LLC | $14.08 | 2019 | |
| Medline Industries LP | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gunjan Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.